Science Explorer Back to mapMap
Discussion
Company · Thunder Bay · Canada

XLV Diagnostics (Canada)

xlvdiagnostics.com/#ROR OpenAlex
Research works
3
▲ 420% vs 2018-21
Citations
100
36.8 per fractional work
Top-10% rate
34.6%
all institutions 10.0%
Open access
18%
world 40%
International
36%
world 18%
XLV Diagnostics (Canada)

Not ranked overall: XLV Diagnostics (Canada) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does XLV Diagnostics (Canada) work in?

In all years, 75% of research at XLV Diagnostics (Canada) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (75%), Immunology and Microbiology (18%), Biochemistry, Genetics and Molecular Biology (7%). It does 1.4× the world's share of Health Sciences.

Health Sciences: 2 fractional works · 75.0% of its workMedicine: 2 fractional works · 75.0% of its workLife Sciences: 1 fractional works · 25.0% of its workImmunology and Microbiology: 0 fractional works · 17.9% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 7.1% of its workALL ITS WORKXLV Diagnostics(Canada)3fractional works, all years
Life Sciences25%Health Sciences75%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Medicine275.0%
    1. Immunology and Microbiology017.9%
    2. Biochemistry, Genetics and Molecular Biology07.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from XLV Diagnostics (Canada)?

The most cited paper from XLV Diagnostics (Canada) is "Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis" (Mark Lebwohl et al., 2015), with 826 citations. Next come "Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)" (210) and "Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment ( SCULPTURE Extension Study)" (200).

Most cited papers
#PaperReleasedCitations
1 Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Mark Lebwohl et al. · New England Journal of Medicine Open access 30 Sep 2015 826
2 Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology 14 May 2015 210
3 Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment ( SCULPTURE Extension Study) Robert Bissonnette, Thomas Anton Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology Open access 14 Feb 2018 200
4 Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population Kim Alexander Papp, Yves P. Poulin, Robert Bissonnette et al. · Journal of the American Academy of Dermatology 21 Sep 2010 101
5 Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study Robert Bissonnette, Thomas Anton Luger, Diamant Thaçi et al. · British Journal of Dermatology 5 Jun 2017 70
All 16 most cited papers, with filters and sorting

Which research topics does XLV Diagnostics (Canada) publish most on?

By volume in 2022-now: Dermatology and Skin Diseases, Nail Diseases and Treatments, Cutaneous lymphoproliferative disorders research and CAR-T cell therapy research.

Dermatology and Skin Diseases: 0 fractional worksNail Diseases and Treatments: 0 fractional worksCutaneous lymphoproliferative disorders research: 0 fractional worksCAR-T cell therapy research: 0 fractional worksPsoriasis: Treatment and Pathogenesis: 0 fractional works
DermatologyEpidemiologyOncologyImmunology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Dermatology and Skin Diseases Dermatology 0 works
  2. 2 Nail Diseases and Treatments Epidemiology 0 works
  3. 3 Cutaneous lymphoproliferative disorders research Dermatology 0 works
  4. 4 CAR-T cell therapy research Oncology 0 works
  5. 5 Psoriasis: Treatment and Pathogenesis Immunology 0 works
  6. 6 Contact Dermatitis and Allergies Dermatology 0 works
  7. 7 Autoimmune Bullous Skin Diseases Pathology and Forensic Medicine 0 works
  8. 8 Spondyloarthritis Studies and Treatments Rheumatology 0 works
  9. 9 Asthma and respiratory diseases Physiology 0 works
  10. 10 Phosphodiesterase function and regulation Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available17.5%not open82.5%

World: 40% of research is openly available.

with international co-authors35.7%domestic only64.3%

World: 18% is written across borders.

How has XLV Diagnostics (Canada)'s research output changed?

Output in 2022-2025 was 420% higher than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is XLV Diagnostics (Canada) as a percentage of every work published that year, 0.0000011% in 2024.

still counting0.000010%0.000020%0.000030%XLV Diagnostics (Canada)0.0000071% in 202520102020

Fractional works of XLV Diagnostics (Canada) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Thunder Bay

All research institutions in Thunder Bay

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about XLV Diagnostics (Canada). Posts are plain text and can be reported.